Skip to main content
. Author manuscript; available in PMC: 2016 Oct 7.
Published in final edited form as: Science. 2015 Sep 10;350(6257):207–211. doi: 10.1126/science.aad0095

Fig. 3. Immune microenvironment cytolytic and immune activity correlates with response to ipilimumab.

Fig. 3

(A) Patients who achieved clinical benefit from immune checkpoint blockade therapy had significantly higher levels of tumor cytolytic activity than those who had minimal or no benefit from ipilimumab (P = 0.039). (B) Patients who achieved clinical benefit from ipilimumab therapy had significantly higher levels of expression immune checkpoint receptors than those who did not (CTLA-4: P = 0.033, PD-L2: P = 0.041). One point is not shown because of an outlying high CTLA-4 expression value in a nonresponder patient (>50 reads per kilobase per million mapped reads). (C) Response to ipilimumab did not correlate with expression of or mutations in HLA alleles (P > 0.05 for all). Asterisks (*) indicate P < 0.05.